Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2015

01-10-2015 | Original Article

Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start?

Authors: Shreya Sengupta, Kristen Wroblewski, Andrew Aronsohn, Nancy Reau, K. Gautham Reddy, Donald Jensen, Helen Te

Published in: Digestive Diseases and Sciences | Issue 10/2015

Login to get access

Abstract

Background

Zinc deficiency has been observed in cirrhosis, but management guidelines do not address screening for zinc deficiency. We aim to determine the prevalence of zinc deficiency in different stages of cirrhosis and to correlate zinc levels with complications of cirrhosis and clinical outcomes. Patients who had a diagnosis of cirrhosis and had serum zinc levels drawn from 2007 to 2011 were identified. Demographics, laboratory data, presence of ascites, encephalopathy, and infection were obtained; Child–Pugh and MELD scores were calculated. Stata software was used for data analysis. A total of 163 patients were included in the study.

Results

The median serum zinc level was 0.47 mcg/ml (IQR 0.37–0.63); 83 % of patients were zinc deficient. Zinc deficiency was more prevalent in patients with Child–Pugh score B or C, and with MELD scores ≥15. Zinc levels were lower in alcoholic, hepatitis C, and cholestatic diseases than in other etiologies of liver disease. Zinc levels correlated with INR (r = −0.56, p < 0.001), bilirubin (r = −0.51, p < 0.001), and albumin (r = 0.68, p < 0.001), and were lower in patients with ascites (0.40 vs. 0.57 mcg/ml, p < 0.001), encephalopathy (0.40 vs. 0.53 mcg/ml, p < 0.001), diuretic use (0.45 vs. 0.535 mcg/ml, p = 0.005), and infection (0.32 vs. 0.51 mcg/ml, p < 0.001). Ascites (p = 0.044) and infection (p = 0.009) were independently associated with zinc levels. Zinc-deficient patients had lower transplant-free survival rates than non-deficient patients.

Conclusion

Zinc deficiency is highly prevalent in cirrhotic patients with Child–Pugh score B or C, and with MELD score ≥15. Zinc deficiency also correlates with disease severity, infection, and a worse transplant-free survival. Screening for zinc deficiency should be considered in this subset of patients.
Literature
1.
go back to reference Bartholomay AF, Robin ED, Vallee RL, Wacker WE. Zinc metabolism in hepatic dysfunction. I. Serum zinc concentrations in Laennec’s cirrhosis and their validation by sequential analysis. N Engl J Med. 1956;255:403–408.CrossRefPubMed Bartholomay AF, Robin ED, Vallee RL, Wacker WE. Zinc metabolism in hepatic dysfunction. I. Serum zinc concentrations in Laennec’s cirrhosis and their validation by sequential analysis. N Engl J Med. 1956;255:403–408.CrossRefPubMed
2.
go back to reference Fredricks RE, Tanaka KR, Valentine WN. Zinc in human blood cells: normal values and abnormalities associated with liver disease. J Clin Investig. 1960;39:1651–1656.PubMedCentralCrossRefPubMed Fredricks RE, Tanaka KR, Valentine WN. Zinc in human blood cells: normal values and abnormalities associated with liver disease. J Clin Investig. 1960;39:1651–1656.PubMedCentralCrossRefPubMed
3.
go back to reference Gil EB, Ruiz MM, Cantero HJ, Diez RA, Rodrigo MM. Zinc and liver cirrhosis. Acta Gastroenterol Belg. 1990;53:292. Gil EB, Ruiz MM, Cantero HJ, Diez RA, Rodrigo MM. Zinc and liver cirrhosis. Acta Gastroenterol Belg. 1990;53:292.
5.
go back to reference Stamoulis I, Kouraklis G, Theocharis S. Zinc and the liver: an active interaction. Dig Dis Sci. 2007;52:1595–1612.CrossRefPubMed Stamoulis I, Kouraklis G, Theocharis S. Zinc and the liver: an active interaction. Dig Dis Sci. 2007;52:1595–1612.CrossRefPubMed
6.
go back to reference Rocchi E, Borella P, Borghi A, et al. Zinc and magnesium in liver cirrhosis. Eur J Clin Invest. 1994;24:149–155.CrossRefPubMed Rocchi E, Borella P, Borghi A, et al. Zinc and magnesium in liver cirrhosis. Eur J Clin Invest. 1994;24:149–155.CrossRefPubMed
7.
go back to reference Poo JL, Rosas-Romero R, Rodriguez F, et al. Serum zinc concentrations in two cohorts of 153 healthy subjects and 100 cirrhotic patients from Mexico City. Dig Dis. 1995;13:136–142.CrossRefPubMed Poo JL, Rosas-Romero R, Rodriguez F, et al. Serum zinc concentrations in two cohorts of 153 healthy subjects and 100 cirrhotic patients from Mexico City. Dig Dis. 1995;13:136–142.CrossRefPubMed
8.
go back to reference Umusig-Quitain P, Gregorio GV. High incidence of zinc deficiency among Filipino children with compensated and decompensated liver disease. J Gastroenterol Hepatol. 2010;25:387–390.CrossRefPubMed Umusig-Quitain P, Gregorio GV. High incidence of zinc deficiency among Filipino children with compensated and decompensated liver disease. J Gastroenterol Hepatol. 2010;25:387–390.CrossRefPubMed
9.
go back to reference Pescovitz MD, Mehta PL, Jindal RM, Milgrom ML, Leapman SB, Filo RS. Zinc deficiency and its repletion following liver transplantation in humans. Clin Transplant. 1996;10:256–260.PubMed Pescovitz MD, Mehta PL, Jindal RM, Milgrom ML, Leapman SB, Filo RS. Zinc deficiency and its repletion following liver transplantation in humans. Clin Transplant. 1996;10:256–260.PubMed
10.
go back to reference Karayalcin S, Arcasoy A, Uzunalimoglu O. Zinc plasma levels after oral zinc tolerance test in nonalcoholic cirrhosis. Dig Dis Sci. 1988;33:1096–1102.CrossRefPubMed Karayalcin S, Arcasoy A, Uzunalimoglu O. Zinc plasma levels after oral zinc tolerance test in nonalcoholic cirrhosis. Dig Dis Sci. 1988;33:1096–1102.CrossRefPubMed
11.
go back to reference Valberg LS, Flanagan PR, Ghent CN, Chamberlain MJ. Zinc absorption and leukocyte zinc in alcoholic and nonalcoholic cirrhosis. Dig Dis Sci. 1985;30:329–333.CrossRefPubMed Valberg LS, Flanagan PR, Ghent CN, Chamberlain MJ. Zinc absorption and leukocyte zinc in alcoholic and nonalcoholic cirrhosis. Dig Dis Sci. 1985;30:329–333.CrossRefPubMed
12.
go back to reference Keeling PW, Ruse W, Bull J, Hannigan B, Thompson RP. Direct measurement of the hepatointestinal extraction of zinc in cirrhosis and hepatitis. Clin Sci. 1981;61:441–444.CrossRefPubMed Keeling PW, Ruse W, Bull J, Hannigan B, Thompson RP. Direct measurement of the hepatointestinal extraction of zinc in cirrhosis and hepatitis. Clin Sci. 1981;61:441–444.CrossRefPubMed
13.
go back to reference Scholmerich J, Becher MS, Kottgen E, et al. The influence of portosystemic shunting on zinc and vitamin A metabolism in liver cirrhosis. Hepatogastroenterology. 1983;30:143–147.PubMed Scholmerich J, Becher MS, Kottgen E, et al. The influence of portosystemic shunting on zinc and vitamin A metabolism in liver cirrhosis. Hepatogastroenterology. 1983;30:143–147.PubMed
14.
go back to reference Ijuin H. Evaluation of pancreatic exocrine function and zinc absorption in alcoholism. Kurume Med J. 1998;45:1–5.CrossRefPubMed Ijuin H. Evaluation of pancreatic exocrine function and zinc absorption in alcoholism. Kurume Med J. 1998;45:1–5.CrossRefPubMed
15.
go back to reference Giroux EL, Durieux M, Schechter PJ. A study of zinc distribution in human serum. Bioinorg Chem. 1976;5:211–218.CrossRefPubMed Giroux EL, Durieux M, Schechter PJ. A study of zinc distribution in human serum. Bioinorg Chem. 1976;5:211–218.CrossRefPubMed
16.
go back to reference Schechter PJ, Giroux EL, Schlienger JL, Hoenig V, Sjoerdsma A. Distribution of serum zinc between albumin and alpha2-macroglobulin in patients with decompensated hepatic cirrhosis. Eur J Clin Invest. 1976;6:147–150.CrossRefPubMed Schechter PJ, Giroux EL, Schlienger JL, Hoenig V, Sjoerdsma A. Distribution of serum zinc between albumin and alpha2-macroglobulin in patients with decompensated hepatic cirrhosis. Eur J Clin Invest. 1976;6:147–150.CrossRefPubMed
17.
go back to reference Lindeman RD, Baxter DJ, Yunice AA, Kraikitpanitch S. Serum concentrations and urinary excretions of zinc in cirrhosis, nephrotic syndrome and renal insufficiency. Am J Med Sci. 1978;275:17–31.CrossRefPubMed Lindeman RD, Baxter DJ, Yunice AA, Kraikitpanitch S. Serum concentrations and urinary excretions of zinc in cirrhosis, nephrotic syndrome and renal insufficiency. Am J Med Sci. 1978;275:17–31.CrossRefPubMed
18.
go back to reference Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology. 1996;23:1084–1092.CrossRefPubMed Marchesini G, Fabbri A, Bianchi G, Brizi M, Zoli M. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology. 1996;23:1084–1092.CrossRefPubMed
19.
go back to reference Riggio O, Ariosto F, Merli M, et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. Dig Dis Sci. 1991;36:1204–1208.CrossRefPubMed Riggio O, Ariosto F, Merli M, et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial. Dig Dis Sci. 1991;36:1204–1208.CrossRefPubMed
20.
go back to reference Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. Lancet. 1984;2:493–495.CrossRefPubMed Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomised controlled trial. Lancet. 1984;2:493–495.CrossRefPubMed
21.
go back to reference Chavez-Tapia NC, Cesar-Arce A, Barrientos-Gutierrez T, Villegas-Lopez FA, Mendez-Sanchez N, Uribe M. A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy. Nutr J. 2013;12:74.PubMedCentralCrossRefPubMed Chavez-Tapia NC, Cesar-Arce A, Barrientos-Gutierrez T, Villegas-Lopez FA, Mendez-Sanchez N, Uribe M. A systematic review and meta-analysis of the use of oral zinc in the treatment of hepatic encephalopathy. Nutr J. 2013;12:74.PubMedCentralCrossRefPubMed
22.
go back to reference Takuma Y, Nouso K, Makino Y, Hayashi M, Takahashi H. Clinical trial: oral zinc in hepatic encephalopathy. Aliment Pharmacol Ther. 2010;32:1080–1090.CrossRefPubMed Takuma Y, Nouso K, Makino Y, Hayashi M, Takahashi H. Clinical trial: oral zinc in hepatic encephalopathy. Aliment Pharmacol Ther. 2010;32:1080–1090.CrossRefPubMed
23.
go back to reference Shankar AH, Prasad AS. Zinc and immune function: the biological basis of altered resistance to infection. Am J Clin Nutr. 1998;68:447S–463S.PubMed Shankar AH, Prasad AS. Zinc and immune function: the biological basis of altered resistance to infection. Am J Clin Nutr. 1998;68:447S–463S.PubMed
24.
go back to reference Wong CP, Ho E. Zinc and its role in age-related inflammation and immune dysfunction. Mol Nutr Food Res. 2012;56:77–87.CrossRefPubMed Wong CP, Ho E. Zinc and its role in age-related inflammation and immune dysfunction. Mol Nutr Food Res. 2012;56:77–87.CrossRefPubMed
25.
go back to reference Fraker PJ, King LE. Reprogramming of the immune system during zinc deficiency. Annu Rev Nutr. 2004;24:277–298.CrossRefPubMed Fraker PJ, King LE. Reprogramming of the immune system during zinc deficiency. Annu Rev Nutr. 2004;24:277–298.CrossRefPubMed
26.
go back to reference Ibs KH, Rink L. Zinc-altered immune function. J Nutr. 2003;133:1452S–1456S.PubMed Ibs KH, Rink L. Zinc-altered immune function. J Nutr. 2003;133:1452S–1456S.PubMed
27.
go back to reference Yoffe B, Pollack S, Ben-Porath E, Zinder O, Barzilai D, Gershon H. Natural killer cell activity in post-necrotic cirrhotic patients as related to hepatitis-B virus infection and plasma zinc levels. Immunol Lett. 1986;14:15–19.CrossRefPubMed Yoffe B, Pollack S, Ben-Porath E, Zinder O, Barzilai D, Gershon H. Natural killer cell activity in post-necrotic cirrhotic patients as related to hepatitis-B virus infection and plasma zinc levels. Immunol Lett. 1986;14:15–19.CrossRefPubMed
28.
go back to reference Allen JI, Perri RT, McClain CJ, Kay NE. Alterations in human natural killer cell activity and monocyte cytotoxicity induced by zinc deficiency. J Lab Clin Med. 1983;102:577–589.PubMed Allen JI, Perri RT, McClain CJ, Kay NE. Alterations in human natural killer cell activity and monocyte cytotoxicity induced by zinc deficiency. J Lab Clin Med. 1983;102:577–589.PubMed
29.
go back to reference Kabu K, Yamasaki S, Kamimura D, et al. Zinc is required for Fc epsilon RI-mediated mast cell activation. J Immunol. 2006;177:1296–1305.CrossRefPubMed Kabu K, Yamasaki S, Kamimura D, et al. Zinc is required for Fc epsilon RI-mediated mast cell activation. J Immunol. 2006;177:1296–1305.CrossRefPubMed
30.
go back to reference Wirth JJ, Fraker PJ, Kierszenbaum F. Zinc requirement for macrophage function: effect of zinc deficiency on uptake and killing of a protozoan parasite. Immunology. 1989;68:114–119.PubMedCentralPubMed Wirth JJ, Fraker PJ, Kierszenbaum F. Zinc requirement for macrophage function: effect of zinc deficiency on uptake and killing of a protozoan parasite. Immunology. 1989;68:114–119.PubMedCentralPubMed
31.
go back to reference Beck FW, Prasad AS, Kaplan J, Fitzgerald JT, Brewer GJ. Changes in cytokine production and T cell subpopulations in experimentally induced zinc-deficient humans. Am J Physiol. 1997;272:E1002–E1007.PubMed Beck FW, Prasad AS, Kaplan J, Fitzgerald JT, Brewer GJ. Changes in cytokine production and T cell subpopulations in experimentally induced zinc-deficient humans. Am J Physiol. 1997;272:E1002–E1007.PubMed
32.
go back to reference Dowd PS, Kelleher J, Guillou PJ. T-lymphocyte subsets and interleukin-2 production in zinc-deficient rats. Br J Nutr. 1986;55:59–69.CrossRefPubMed Dowd PS, Kelleher J, Guillou PJ. T-lymphocyte subsets and interleukin-2 production in zinc-deficient rats. Br J Nutr. 1986;55:59–69.CrossRefPubMed
33.
go back to reference DePasquale-Jardieu P, Fraker PJ. Interference in the development of a secondary immune response in mice by zinc deprivation: persistence of effects. J Nutr. 1984;114:1762–1769.PubMed DePasquale-Jardieu P, Fraker PJ. Interference in the development of a secondary immune response in mice by zinc deprivation: persistence of effects. J Nutr. 1984;114:1762–1769.PubMed
Metadata
Title
Screening for Zinc Deficiency in Patients with Cirrhosis: When Should We Start?
Authors
Shreya Sengupta
Kristen Wroblewski
Andrew Aronsohn
Nancy Reau
K. Gautham Reddy
Donald Jensen
Helen Te
Publication date
01-10-2015
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2015
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3613-0

Other articles of this Issue 10/2015

Digestive Diseases and Sciences 10/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.